Marianne Ellen Pavel

Medizinische Fakultät Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Professur für Endokrinologie

Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study (2018) Crona J, Lamarca A, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Vidal Trueba H, et al. Conference contribution Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution IFN-α in advanced well-differentiated neuroendocrine tumors: the neglected drug? (2018) Amoroso V, Pavel ME, Claps M, Roca E, Ravanelli M, Maroldi R, Oberg K, Berruti A Journal article Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/depot 120mg in the CLARINET open-label extension (2018) Pavel ME, Cwikla J, Wolin E, Phan A, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution How to Perform Contrast Enhanced Oncologic Staging MRI of Abdomen and Pelvis with a Hepatocyte Specific Agent in a Large Bore MR Scanner: Optimizing Extrahepatic Tumor Evaluation in Neuroendocrine Neoplasms (2018) Fehrenbach U, Fahlenkamp U, Prasad , Pavel ME, Geisel D, Denecke T Conference contribution Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study (2018) Wolin EM, Pavel ME, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period (2018) Hoersch D, Kulke MH, Caplin ME, Anthony LB, Bergsland E, Oberg K, Warner RRP, et al. Conference contribution Integrated Safety Analysis of Telotristat Ethyl in Patients With Carcinoid Heart Disease (2018) Lapuerta P, Kulke MH, Pavel ME, Biran T, Fleming R, Zacks JS, Hoffmanns P, Warner RRP Conference contribution ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment (2018) Yao JC, Fazio N, Li D, Pavel ME, Strosberg J, Bergsland E, Ruszniewski P, et al. Conference contribution BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS (2018) Mirakhur B, Pavel ME, Pommier RF, Fisher GA, Phan AT, Massien C, Liyanage N, et al. Journal article